MBT1: A Potential Drug Target for Various Diseases (G84456)

Target Name: L3MBTL3

NCBI ID: G84456

L3MBTL3

MBT1: A Potential Drug Target for Various Diseases

L3MBTL3 (MBT1), also known as L3MBTL3-containing intercellular adhesion molecule (ICAM), is a protein that is expressed in various tissues and cells throughout the body. It is a member of the integrin alpha-2 (IAAG) family and is involved in cell-cell adhesion, migration, and invasion.

MBT1 has been identified as a potential drug target in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique structure and function have made it an attractive target for small molecule inhibitors.

One of the main reasons for the interest in MBT1 as a drug target is its role in cell-cell adhesion. MBT1 is a critical protein for the formation of tight junctions, which are essential for maintaining tissue structure and function. primary barrier that is essential for maintaining tissue structure and function. MBT1 forms tight junction proteins between cells, which is key to maintaining tissue structure and function.

MBT1 is also involved in the regulation of cell migration and invasion. Its structure and function allow it to interact with various adhesion molecules, including cadherins, integrins, and vimentin. These interactions enable MBT1 to regulate cell migration and invasion. Its structure and function enable it to interact with a variety of adhesion molecules, including cadherins, integrins and vimentin.

MBT1 is also associated with various diseases, including cancer. Its role in cell-cell adhesion and migration makes it a potential target for cancer therapies. Cancer therapeutic targets.

A number of small molecules have been identified as potential inhibitors of MBT1. These molecules include inhibitors of its extracellular domain (ECD), N-terminal domain, and C-terminal domain. Inhibitors, including inhibitors of its exocrine domain (ECD), internal domain (N-terminal domain) and C-terminal domain.

One of the most promising inhibitors of MBT1 is a small molecule called TK-152. TK-152 is a inhibitor of MBT1's ECD and has been shown to be effective in preclinical studies in treating various diseases, including cancer. Promising molecules for ECD have shown efficacy in clinical trials for treating various diseases, including cancer.

Another promising inhibitor of MBT1 is a small molecule called IPT-132. IPT-132 is an inhibitor that inhibits the internal domain of MBT1. Its mechanism of action is by binding to the internal domain of MBT1 and preventing it from binding to the extracellular matrix. IPT-132 is an inhibitor that blocks MBT1 from binding to the extracellular matrix by binding to its internal domain.

MBT1 has also been identified as a potential biomarker for some diseases. Its role in cell-cell adhesion and migration makes it an attractive target for biomarkers that can be used to diagnose or monitor disease. landmark. Its cell-to-cell connectivity and migration capabilities make it an attractive biomarker for diagnosing or monitoring disease.

In conclusion, MBT1 is a protein that is involved in cell-cell adhesion, migration, and invasion. Its unique structure and function have made it an attractive target for small molecule inhibitors. Its unique structure and functionality make it an attractive target for small molecule inhibitors.

Protein Name: L3MBTL Histone Methyl-lysine Binding Protein 3

Functions: Is a negative regulator of Notch target genes expression, required for RBPJ-mediated transcriptional repression (PubMed:29030483). It recruits KDM1A to Notch-responsive elements and promotes KDM1A-mediated H3K4me demethylation (PubMed:29030483). Involved in the regulation of ubiquitin-dependent degradation of a set of methylated non-histone proteins, including SOX2, DNMT1 and E2F1. It acts as an adapter recruiting the CRL4-DCAF5 E3 ubiquitin ligase complex to methylated target proteins (PubMed:30442713, PubMed:29691401). Required for normal maturation of myeloid progenitor cells (By similarity)

The "L3MBTL3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about L3MBTL3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets